What is the appropriate bridging therapy for a patient with pulmonary tuberculosis whose treatment is interrupted due to hepatotoxicity?

Bridging Therapy for Pulmonary TB During Treatment Interruption Due to Hepatotoxicity

For smear-positive or clinically unwell patients with pulmonary TB who develop hepatotoxicity requiring discontinuation of all hepatotoxic drugs (isoniazid, rifampicin, pyrazinamide), inpatient bridging therapy with streptomycin plus ethambutol should be initiated immediately to maintain tuberculosis control while the liver recovers. 1

Immediate Discontinuation Criteria

All hepatotoxic anti-TB drugs must be stopped when any of the following occur:

• AST/ALT ≥ 5 × upper limit of normal (ULN) in asymptomatic patients 1, 2
• AST/ALT ≥ 3 × ULN with hepatitis symptoms (nausea, vomiting, abdominal pain, jaundice, fever) 1, 2
• Any elevation of bilirubin above baseline, regardless of transaminase levels 1
• Clinical jaundice or unexplained deterioration 1

Ethambutol may be continued during this period as it is non-hepatotoxic. 1

Bridging Therapy Protocol

For Smear-Positive or Clinically Unwell Patients

Inpatient regimen: Streptomycin + Ethambutol 1

• This combination maintains anti-TB activity while avoiding hepatotoxic agents 1
• Continue until liver enzymes normalize (ALT/AST < 2 × ULN and bilirubin returns to baseline) 1
• Recovery typically requires 2–8 weeks for hepatocellular injury 1

Monitoring requirements during bridging:

• Baseline renal function and weekly creatinine for streptomycin nephrotoxicity 1
• Baseline audiometry to detect ototoxicity 1
• Visual acuity monitoring for ethambutol 1

For Clinically Stable, Non-Infectious Patients

• Anti-TB drugs may be deferred entirely until liver function normalizes 1
• This approach is appropriate only when there is no risk of disease progression or transmission 1

Exclusion of Alternative Causes

Before attributing liver injury to anti-TB medications, systematically rule out:

• Viral hepatitis: Test HBsAg and anti-HCV antibodies; if HBsAg positive, add HBV DNA quantification 1
• Biliary tract disease: Abdominal ultrasound or CT 1
• Alcohol use: Assess current and recent consumption 1
• Other hepatotoxic medications: Review acetaminophen, statins, herbal supplements 1
• HIV-related hepatobiliary disease in HIV-positive patients 1

Sequential Drug Re-introduction After Hepatic Recovery

Re-introduction may begin only when:

• ALT/AST ≤ 2 × ULN 1
• Bilirubin returned to baseline 1
• Patient is asymptomatic 1

Step-by-Step Re-introduction Protocol

Daily clinical and biochemical monitoring (ALT, AST, bilirubin) is mandatory throughout. 1

Step	Drug	Starting Dose	Escalation	Target Dose
1. Isoniazid	50 mg once daily	Increase to 300 mg after 2–3 days if tolerated; maintain 300 mg for 2–3 days before adding next drug	300 mg daily	[1]
2. Rifampicin	75 mg once daily	Increase to 300 mg after 2–3 days; then to 450 mg (<50 kg) or 600 mg (≥50 kg) after another 2–3 days; maintain full dose for 2–3 days	450–600 mg daily	[1]
3. Pyrazinamide	250 mg once daily	Increase to 1.0 g after 2–3 days; then to 1.5 g (<50 kg) or 2.0 g (≥50 kg) after another 2–3 days	1.5–2.0 g daily	[1]

Stop the current drug immediately if during re-introduction:

• AST/ALT ≥ 3 × ULN with symptoms, OR 1
• AST/ALT ≥ 5 × ULN without symptoms, OR 1
• Any bilirubin elevation 1

Modified Regimens When Re-introduction Fails

If Pyrazinamide is the Offending Agent

• Continue rifampicin + isoniazid for a total of 9 months 1
• Add ethambutol for the first 2 months 1
• Pyrazinamide should never be re-introduced after causing severe hepatotoxicity with bilirubin elevation 1

If Rifampicin Cannot Be Re-introduced

• Use isoniazid + pyrazinamide + ethambutol + levofloxacin (750–1000 mg daily) for 12–18 months 1
• Add streptomycin during the first 2 months 1

If Both Isoniazid and Rifampicin Must Be Avoided

• Employ ethambutol + levofloxacin + cycloserine + an injectable agent for 18–24 months under specialist supervision 1
• Avoid aminoglycosides in severe liver disease due to increased bleeding risk from thrombocytopenia and coagulopathy 1

High-Risk Patient Monitoring

Patients at high risk for hepatotoxicity require intensified monitoring:

High-risk groups include: 1, 2

• Chronic liver disease
• Hepatitis B/C coinfection
• HIV infection
• Age > 35 years
• Chronic alcohol use
• Concurrent hepatotoxic medications
• Pregnancy or ≤ 3 months postpartum

Monitoring schedule: 1

• Weekly liver function tests for the first 2 weeks
• Every 2 weeks for the next 2 months
• Monthly thereafter

Special consideration for HBsAg-positive patients:

• Quantify HBV DNA; levels > 2000 IU/mL predict fatal drug-induced liver injury (adjusted HR 4.40) and warrant prompt antiviral therapy 1

Critical Pitfalls to Avoid

• Never continue hepatotoxic drugs after meeting discontinuation thresholds – this dramatically increases the risk of acute liver failure 1
• Pyrazinamide is the most hepatotoxic first-line agent and should be avoided in patients with pre-existing liver abnormalities 3, 1
• Do not perform routine LFT monitoring in standard-risk patients with normal baseline values unless symptoms develop 1
• Alcohol must be avoided completely during TB treatment, as it markedly increases hepatotoxicity risk 1
• The majority of hepatotoxicity occurs within the first 2–8 weeks of therapy, with peak around week 4, but late-onset cases can occur, requiring ongoing vigilance 1

Patient Education

Instruct patients to report immediately any hepatitis symptoms: 1

• Nausea or vomiting
• Abdominal pain
• Jaundice or dark urine
• Fever
• Unexplained malaise